STX-100
Based on 1 Customer Validation
STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 1439902-67-6
- Molecular Weight:144.88 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
αvβ6 |
STX-100 (1 h pretreatment) exhibits minimal inhibitory effects on TGF-β1-induced morphological and nuclear changes in A549 cells[3].
STX-100 (1 h pretreatment) does not substantially alter actin cytoskeletal organization in A549 cells and does not prevent TGF-β1-associated changes in actin distribution[3].
STX-100 (1 h pretreatment) has limited inhibitory effects on TGF-β1-induced morphological and nuclear changes in MCF10A cells[3].
STX-100 (1 h pretreatment) does not reverse TGF-β1-induced changes in cell organization, cell-cell adhesion, nuclear morphology, or extracellular matrix structure in MCF10A cells[3].
STX-100 (1 h pretreatment) does not substantially alter TGF-β1-driven changes in fibronectin fibril organization in MCF10A cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rhesus monkey (4-8 years old)[2]
-
Dosage:3 mg/kg
-
Administration:s.c.; weekly; 8 weeks
-
Result:Showed three of five animals developed acute rejection on post-randomization days 21, 28, and 35, with sacrifice on days 26, 35, and 35 respectively.
Had two of five animals complete the 8-week course with good allograft function.
Demonstrated significantly decreased postrandomization rejection-free survival compared to placebo-treated animals.
Showed average avb6 staining intensity was lower compared to placebo-treated animals.
Exhibited significantly lower levels of LAP in tubular cytoplasm, plasma cells, and interstitial infiltrates in rejecting allografts compared to animals that rejected on standard immunosuppression alone.
Showed lower LTBP-1 in tubular cytoplasm in rejecting allografts compared to animals that rejected on standard immunosuppression alone.
Demonstrated lower active TGF-b1 in interstitial infiltrates in rejecting allografts compared to animals that rejected on standard immunosuppression alone.
Showed a mean serum total TGF-b1 increase of 31,474 pg/mL from randomization to sacrifice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Human Integrin alpha V beta 6 (ITGAV&ITGB6) can bind STX-100. The EC50 for this effect is 131.5 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells with STX-100 (HY-P990667, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1439902-67-6
-
Appearance Liquid
-
Molecular Weight 144.88 kDa
-
Color Colorless to light yellow
-
Synonyms
BG00011
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Crunkhorn S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nat Rev Drug Discov. 2012 Mar 30;11(4):260. [Content Brief]
[2]. Lo DJ, et al. Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant. 2013;13(12):3085-3093. [Content Brief]
[4]. Sylvers PH, et al. Mitigation of harmful algal blooms caused by Alexandrium catenella and reduction in saxitoxin accumulation in bivalves using cultivable seaweeds. Harmful Algae. 2021;105:102056. [Content Brief]
[5]. Raghu G, et al. Randomized Phase IIa Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Nov 1;206(9):1166-1168. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
STX-100 Related Classifications
HY-P990667 Related Classifications
Powered by Bioz
- STX-100
- 1439902-67-6
- BG00011
- STX100
- STX 100
- BG 00011
- BG-00011
- Integrin
- TGF-beta/Smad
- MCF10A cells
- A549 cells
- epithelial-mesenchymal transition
- latency-associated peptide
- transforming growth factor-β
- acute renal allograft rejection
- rhesus macaques
- αVβ6 integrin
- latent TGFβ binding protein-1
- idiopathic pulmonary fibrosis
- Inhibitor
- inhibitor
- inhibit